The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| VRTX | -10.59% | +104.25% | +15.34% | +9,357% |
| S&P | +19.89% | +109.18% | +15.89% | +1,707% |
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
These exchange-traded funds track companies in this biotech space.
Vertex appears to be by far the better buy right now.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.99B | 13.3% |
| Gross Profit | $2.58B | 14.0% |
| Gross Margin | 86.35% | 0.5% |
| Market Cap | $114.33B | -5.5% |
| Market Cap / Employee | $18.74M | 0.0% |
| Employees | 6.1K | 13.0% |
| Net Income | $1.03B | 128.7% |
| EBITDA | $1.23B | 25.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.98B | 8.8% |
| Accounts Receivable | $1.89B | 14.3% |
| Inventory | 1.5K | 63.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.53B | 63.6% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 16.47% | 18.9% |
| Return On Invested Capital | 17.80% | -4.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $927.40M | 124.3% |
| Operating Free Cash Flow | $1.07B | 128.6% |
| Metric | Q4 2023 | Q1 2024 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 29.29 | 27.12 | 31.82 | - | |
| Price to Book | 7.67 | 6.64 | 7.59 | 6.93 | 6.24% |
| Price to Sales | 11.43 | 9.55 | 11.39 | 10.12 | -13.68% |
| Price to Tangible Book Value | 8.74 | 7.57 | 8.59 | 7.64 | 4.95% |
| Price to Free Cash Flow TTM | 31.81 | 29.36 | 32.93 | - | |
| Enterprise Value to EBITDA | 98.12 | 88.74 | 114.88 | 89.96 | -24.23% |
| Free Cash Flow Yield | 3.1% | 3.4% | 3.0% | - | |
| Return on Equity | -3.0% | -3.2% | -5.6% | 22.8% | -802.89% |
| Total Debt | $1.70B | $1.75B | $1.65B | $1.53B | 63.64% |
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
We examine three biotech companies' past performances and future outlooks.
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
VRTX earnings call for the period ending December 31, 2024.
VRTX earnings call for the period ending September 30, 2024.
VRTX earnings call for the period ending June 30, 2024.
VRTX earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
